Roche

News

FDA starts swift review of Regeneron’s CD20 bispecific

The FDA has started a priority review of Regeneron’s CD20xCD3 bispecific antibody odronextamab, seeking a broader label than other drugs in the class.

News

Roche inks pipeline deals with Orionis, PeptiDream

Roche has bolstered its R&D pipeline in oncology and neuroscience with a pair of partnerships with Orionis Biosciences and PeptiDream, parting with upfront cash of $87

News

EU has its first RoActemra biosimilar, from Fresenius Kabi

The European Commission has approved the first biosimilar version of Actemra/RoActemra, Roche’s $3 billion blockbuster, from German drugmaker Fresenius Kabi.

News

Lift for Roche as Alnylam drug lowers blood pressure

Just weeks after wagering $310 million upfront on the rights to Alnylam's hypertension therapy zilebesiran on the strength of phase 1 data, Roche has been rewarded by a po

News

FDA starts review of Roche's PNH drug crovalimab

Roche could be just months away from FDA approval of its anti-complement C5 antibody crovalimab, after the US regulator started a review of its marketing application as a

News

Roche seeks early-stage lung cancer use for Alecensa

Roche plans to file its Alecensa drug for use in early-stage ALK-positive non-small cell lung cancer (NSCLC), potentially making it the first targeted therapy for these pa

FDA starts swift review of Regeneron’s CD20 bispecific

Roche inks pipeline deals with Orionis, PeptiDream

EU has its first RoActemra biosimilar, from Fresenius Kabi

Lift for Roche as Alnylam drug lowers blood pressure

FDA starts review of Roche's PNH drug crovalimab

Roche seeks early-stage lung cancer use for Alecensa

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

Roche

Editor's Picks